Clinical Trial

Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial

Study acronym: EvER-ILD2
Unknown Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2024 (before its estimated July 16, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main objective of the EvER-ILD2 study is to evaluate the efficacy on lung function at 6 months of one course rituximab (2 infusions) comparatively to one course of placebo (2 infusions) in a broad range of progressive ILD patients with inflammatory component.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05596786
Lead Sponsor University Hospital, Tours
Conditions Lung Diseases
Enrollment 126 participants
Start Date 2023-01-16
Primary Completion 2026-07-16 (estimated)
Study Completion 2026-07-16 (estimated)
Updated on ClinicalTrials.gov 2024-07-24